HDAC9 and diffuse large B-cell lymphoma: Notably, the novel dual HDAC and PI3K inhibitor CUDC-907 demonstrated excellent activity (ORR 55%) and tolerability (43% of grade ≥ 3 adverse events) in a phase I trial in patients with DLBCL, FL, and HL [203].